Alpha-Fetoprotein (AFP) Blood Test

Key Takeaways

Alpha-fetoprotein (AFP) is a fetal protein measured in blood to screen for neural tube defects, chromosomal abnormalities, and certain cancers.

AFP testing serves dual clinical purposes: prenatal screening (typically weeks 15-20 of gestation) and oncology monitoring (hepatocellular carcinoma, germ cell tumors).

Normal AFP ranges vary by age and clinical context-non-pregnant adults <10 ng/mL, pregnant women follow gestational-week-specific cutoffs, abnormal results require ultrasound or amniocentesis follow-up.

Practice management software like Pabau streamlines AFP test ordering, specimen tracking, result documentation, and multi-disciplinary communication through digital forms and structured client records.

Download your free alpha-fetoprotein (AFP) test template

The alpha-fetoprotein (AFP) test is a blood screening tool with two distinct clinical roles: identifying fetal abnormalities during pregnancy and monitoring for cancer in non-pregnant populations. This guide provides practitioners with the clinical context, reference ranges, and documentation workflows for integrating AFP testing into prenatal and oncology care pathways. Structured intake forms ensure consistency across test ordering, specimen labeling, and result reporting.

What is the alpha-fetoprotein (AFP) test?

The alpha-fetoprotein (AFP) test measures levels of AFP protein in blood serum. AFP is synthesized primarily by the fetal liver and yolk sac during pregnancy. In non-pregnant adults, however, AFP should be minimal; elevated levels signal either pregnancy-related conditions or systemic disease.

Clinicians order AFP for two reasons: prenatal assessment (typically second trimester, weeks 15-20) to screen for neural tube defects and chromosomal abnormalities, and post-natal oncology monitoring (hepatocellular carcinoma, non-seminomatous germ cell tumors). AFP is classified as a tumor marker when used outside pregnancy.

Clinical documentation software supports secure documentation of test ordering, specimen details, reference ranges, and results interpretation, protecting patient data and establishing audit trails for clinical decision-making.

Clinical uses and indications for AFP testing

The primary indications for AFP testing align with its two clinical contexts:

• Prenatal screening: screens for neural tube defects (spina bifida, anencephaly) and chromosomal abnormalities (Down syndrome, trisomy 18) via maternal serum between 15 and 20 weeks gestation
• Hepatocellular carcinoma (HCC): diagnostic and monitoring tool for at-risk populations (cirrhosis, hepatitis B/C, familial risk) with AFP >400 ng/mL suggestive of HCC
• Germ cell tumors: testicular and ovarian non-seminomatous germ cell tumors (NSGCTs) frequently elevate AFP, often ordered alongside hCG (human chorionic gonadotropin) for diagnostic accuracy
• Benign liver disease: cirrhosis, hepatitis, and benign hepatic lesions may transiently elevate AFP; not diagnostic alone
• Other malignancies: gastric cancer, biliary tract cancer such as gallbladder cancer, ICD-10 code C23, and ovarian germ cell tumors occasionally present with elevated AFP

The dual-purpose nature of AFP testing, prenatal versus oncology, requires careful context documentation to guide appropriate follow-up and prevent clinical misinterpretation.

AFP test in pregnancy: prenatal screening overview

Prenatal AFP screening is part of maternal serum screening performed in the second trimester. Fertility clinic workflows and OB/GYN practices integrate AFP as one component of multi-marker panels: the triple screen (AFP, hCG, uE3) or quad screen (triple plus inhibin A).

Elevated maternal AFP (>2.0-2.5 multiples of median [MoM]) may indicate neural tube defects, abdominal wall defects, or placental abnormalities. By contrast, low AFP (<0.5 MoM) is associated with trisomy 21 (Down syndrome) and trisomy 18 (Edwards syndrome). Timing matters too: testing between 15 and 20 weeks allows sonographic follow-up before 24 weeks if needed.

Patient education and communication prior to testing reduces anxiety and supports informed consent, particularly when results prompt follow-up ultrasound or amniocentesis.

AFP as a tumor marker: liver cancer and germ cell tumors

In non-pregnant adults, AFP >10-20 ng/mL warrants investigation, and AFP >400 ng/mL is strongly associated with hepatocellular carcinoma, particularly in patients with underlying cirrhosis or viral hepatitis. In patients with cirrhosis, AFP is often monitored alongside liver elastography, billed under CPT code 91200, as part of routine HCC surveillance. Benign liver disease, such as cirrhosis without HCC or chronic hepatitis, can also elevate AFP transiently.

For germ cell tumors, AFP is more specific: >50% of non-seminomatous testicular tumors and 60-70% of ovarian germ cell tumors produce elevated AFP. AFP and hCG are routinely ordered together, and the pattern of both markers guides prognostic stratification and treatment monitoring.

How the AFP test is performed: specimen collection

AFP testing requires a blood serum sample collected via venipuncture into a serum separator tube (SST, typically a gold-top or tiger-top tube). Following collection, the specimen must be processed, centrifuged, and separated; serum is then frozen for storage or transported to the reference laboratory for analysis.

• No fasting required for AFP
• Specimen stability: room temperature up to 8 hours; refrigerated up to 72 hours; frozen indefinitely
• Hemolyzed or visibly contaminated specimens should be rejected and re-drawn
• Chain of custody documentation is mandatory for HIPAA and accreditation compliance

AFP test normal range and reference values

Reference ranges for AFP vary by laboratory platform and gestational context. For example, representative ranges include the following (note: laboratory-specific cutoffs apply):

Always consult the performing laboratory’s reference range documentation, since ranges differ by assay platform, population demographics, and smoking status.

Interpreting AFP test results

High AFP (prenatal context): Elevated maternal AFP may indicate neural tube defects (NTDs: spina bifida, anencephaly), abdominal wall defects, Down syndrome (less common with elevated AFP; typically has low AFP), placental abnormalities, or multiple gestation. Follow-up: targeted ultrasound, genetic counseling, possible amniocentesis.

Low AFP (prenatal context): Decreased AFP combined with elevated hCG and low uE3 suggests increased risk of Down syndrome. With low hCG and elevated inhibin A, trisomy 18 risk rises. Comprehensive clinical record keeping ensures results are interpreted in the context of maternal age, ultrasound dating, and additional screening markers.

Elevated AFP (non-pregnant): Investigate for HCC (if cirrhosis/hepatitis present), germ cell tumors, or benign liver disease. AFP >20 ng/mL warrants imaging, and >400 ng/mL is concerning for HCC. Serial AFP monitoring, every 4-12 weeks, assesses treatment response in HCC or germ cell tumor patients.

According to MedlinePlus, patient-facing AFP test information supports shared decision-making conversations.

Next steps after abnormal AFP results

Abnormal AFP results require systematic follow-up:

1. Confirm gestational age (prenatal): ultrasound dating ensures accurate MoM interpretation; even 1-2 week error shifts cutoffs significantly
2. Repeat AFP if questionable: specimen hemolysis or labeling error may cause false elevation; recollection clarifies
3. Order co-marker panel: if not already done, hCG and uE3 (triple screen) or inhibin A (quad screen) refine risk stratification
4. Referral to maternal-fetal medicine (MFM): for abnormal prenatal results, followed by high-level ultrasound and genetic counseling
5. Consider amniocentesis: if NTD or chromosomal risk is elevated and patient accepts invasive testing
6. Imaging (non-pregnant): ultrasound or CT if AFP >20 ng/mL to exclude HCC or malignancy
7. Multidisciplinary communication: HIPAA-compliant documentation ensures OB/GYN, oncology, and primary care teams are aligned on next steps

AFP test documentation template for clinicians

The downloadable template provided above offers a structured framework for documenting the entire AFP test workflow. Key sections include:

Digital form templates integrate AFP ordering workflows directly into patient record systems, reducing manual transcription and improving legibility. Structured client records maintain comprehensive test history for longitudinal monitoring.

Streamline AFP testing with Pabau

Pabau's digital forms, structured client records, and compliance tools simplify AFP test ordering, specimen tracking, and result documentation for prenatal and oncology workflows.

Book a demo

Regulatory and compliance considerations

AFP testing falls under CLIA (Clinical Laboratory Improvement Amendments) and CAP (College of American Pathologists) accreditation in the US. Labs must demonstrate competency in specimen handling, result accuracy, and quality assurance. All HIPAA-compliant documentation of AFP orders and results is mandatory to protect patient privacy.

NCBI StatPearls provides clinical context for AFP in hepatocellular carcinoma and germ cell tumor management, supporting evidence-based ordering and interpretation.

Who is the AFP test helpful for?

Prenatal care providers: OB/GYNs, midwives, and maternal-fetal medicine specialists use AFP as part of second-trimester screening protocols to identify pregnancies at increased risk of neural tube defects and chromosomal abnormalities.

Hepatology and oncology clinics: physicians monitoring patients with cirrhosis, hepatitis B/C, or known HCC rely on serial AFP to assess disease progression and treatment response.

Medical oncologists: specializing in testicular and ovarian germ cell tumors use AFP (and hCG) for risk stratification, treatment monitoring, and recurrence detection.

Primary care and functional medicine clinics: may order AFP as part of comprehensive health assessment or cancer risk screening in at-risk populations (family history, chronic liver disease). Nurse practitioners increasingly lead these practices, and our guide to nurse practitioner private practice covers the operational side of running one.

Benefits of using the AFP test documentation template

Compliance and audit readiness: Structured templates create defensible documentation for regulatory inspections (CLIA, CAP) and malpractice review, which protects clinicians during audits.

Clinical consistency: Standard fields reduce variability in test ordering and result interpretation across the practice team.

Patient safety: Clear documentation of gestational age, reference range, and follow-up plan prevents misinterpretation or missed diagnoses.

Longitudinal monitoring: Organized records enable clinicians to track serial AFP levels for HCC or germ cell tumor surveillance.

Team communication: When shared across clinical compliance tracking systems, the template ensures OB/GYN, oncology, and laboratory teams stay aligned.

Conclusion

The alpha-fetoprotein (AFP) test is a clinically essential tool spanning prenatal medicine and oncology. Proper specimen collection, result interpretation within gestational or clinical context, and systematic follow-up of abnormal findings are prerequisites for safe, effective use. The downloadable documentation template standardizes these workflows, supporting compliance, patient safety, and multidisciplinary communication. Integrating AFP ordering and result tracking into your practice management system helps ensure no abnormal result goes unaddressed.

Expert resources

Continue your research

Documenting a liver work-up alongside AFP? Our abdominal physical exam template standardizes the findings clinicians record during HCC surveillance.

Billing for the blood draw itself? HCPCS code A4209 covers the sterile syringe supplies used for AFP specimen collection.

Supporting patients through follow-up monitoring? Our wellness journal template gives patients a simple way to track symptoms while awaiting results.

Frequently asked questions